PMID- 36128677
OWN - NLM
STAT- MEDLINE
DCOM- 20230116
LR  - 20230116
IS  - 1545-7222 (Electronic)
IS  - 0895-0172 (Linking)
VI  - 35
IP  - 1
DP  - 2023 Winter
TI  - Anti-N-Methyl-d-Aspartate Receptor Antibody Testing in First-Episode Psychosis: 
      Universal or Targeted Testing.
PG  - 98-101
LID - 10.1176/appi.neuropsych.21080214 [doi]
AB  - Anti-N-methyl-d-aspartate receptor (NMDAR) encephalitis is an immune-mediated 
      disorder that typically presents with rapid development of neuropsychiatric 
      symptoms. As a potentially reversible cause of psychosis, there have been calls 
      internationally for routine serological screening for anti-NMDAR antibodies in 
      patients presenting with first-episode psychosis (FEP). Increased serological 
      testing has, however, exposed several limitations of universal screening and 
      rekindled debate as to which patients should be tested. Screening criteria have 
      been proposed for high-risk clinical features in FEP in which antineuronal 
      antibody testing is indicated. The authors present a clinical vignette and a 
      service audit as well as discuss the limitations of universal screening 
      advocating instead for targeted testing for antineuronal antibodies in patients 
      diagnosed as having FEP.
FAU - Cohn, Sarah L
AU  - Cohn SL
AD  - Neuropsychiatric Institute, Prince of Wales Hospital, Sydney, Australia (Cohn, 
      Mohan); University of New South Wales, Sydney (Cohn, Mohan, Lappin, Curtis); 
      South Eastern Sydney Local Health District, Sydney (Cohn, Mohan, Lappin, Curtis); 
      Mindgardens Neuroscience Network, Sydney (Curtis); Child and Youth Research 
      Group, QIMR Berghofer Medical Research Institute, and Early Psychosis Service, 
      Metro North Mental Health Service, Herston, Australia (Scott); Queensland Centre 
      for Mental Health Research, The Park Centre for Mental Health, Wacol, Australia 
      (Scott).
FAU - Mohan, Adith
AU  - Mohan A
AD  - Neuropsychiatric Institute, Prince of Wales Hospital, Sydney, Australia (Cohn, 
      Mohan); University of New South Wales, Sydney (Cohn, Mohan, Lappin, Curtis); 
      South Eastern Sydney Local Health District, Sydney (Cohn, Mohan, Lappin, Curtis); 
      Mindgardens Neuroscience Network, Sydney (Curtis); Child and Youth Research 
      Group, QIMR Berghofer Medical Research Institute, and Early Psychosis Service, 
      Metro North Mental Health Service, Herston, Australia (Scott); Queensland Centre 
      for Mental Health Research, The Park Centre for Mental Health, Wacol, Australia 
      (Scott).
FAU - Lappin, Julia M
AU  - Lappin JM
AD  - Neuropsychiatric Institute, Prince of Wales Hospital, Sydney, Australia (Cohn, 
      Mohan); University of New South Wales, Sydney (Cohn, Mohan, Lappin, Curtis); 
      South Eastern Sydney Local Health District, Sydney (Cohn, Mohan, Lappin, Curtis); 
      Mindgardens Neuroscience Network, Sydney (Curtis); Child and Youth Research 
      Group, QIMR Berghofer Medical Research Institute, and Early Psychosis Service, 
      Metro North Mental Health Service, Herston, Australia (Scott); Queensland Centre 
      for Mental Health Research, The Park Centre for Mental Health, Wacol, Australia 
      (Scott).
FAU - Curtis, Jackie
AU  - Curtis J
AD  - Neuropsychiatric Institute, Prince of Wales Hospital, Sydney, Australia (Cohn, 
      Mohan); University of New South Wales, Sydney (Cohn, Mohan, Lappin, Curtis); 
      South Eastern Sydney Local Health District, Sydney (Cohn, Mohan, Lappin, Curtis); 
      Mindgardens Neuroscience Network, Sydney (Curtis); Child and Youth Research 
      Group, QIMR Berghofer Medical Research Institute, and Early Psychosis Service, 
      Metro North Mental Health Service, Herston, Australia (Scott); Queensland Centre 
      for Mental Health Research, The Park Centre for Mental Health, Wacol, Australia 
      (Scott).
FAU - Scott, James G
AU  - Scott JG
AD  - Neuropsychiatric Institute, Prince of Wales Hospital, Sydney, Australia (Cohn, 
      Mohan); University of New South Wales, Sydney (Cohn, Mohan, Lappin, Curtis); 
      South Eastern Sydney Local Health District, Sydney (Cohn, Mohan, Lappin, Curtis); 
      Mindgardens Neuroscience Network, Sydney (Curtis); Child and Youth Research 
      Group, QIMR Berghofer Medical Research Institute, and Early Psychosis Service, 
      Metro North Mental Health Service, Herston, Australia (Scott); Queensland Centre 
      for Mental Health Research, The Park Centre for Mental Health, Wacol, Australia 
      (Scott).
LA  - eng
PT  - Journal Article
DEP - 20220921
PL  - United States
TA  - J Neuropsychiatry Clin Neurosci
JT  - The Journal of neuropsychiatry and clinical neurosciences
JID - 8911344
RN  - 0 (aspartic acid receptor)
RN  - 0 (Receptors, N-Methyl-D-Aspartate)
SB  - IM
MH  - Humans
MH  - Receptors, N-Methyl-D-Aspartate
MH  - *Psychotic Disorders/etiology
MH  - *Anti-N-Methyl-D-Aspartate Receptor Encephalitis/diagnosis/complications
MH  - Diagnosis, Differential
OTO - NOTNLM
OT  - Autoimmune psychosis
OT  - Early psychosis
OT  - Guidelines
OT  - Immunology
OT  - Schizophrenia
OT  - Screening
EDAT- 2022/09/22 06:00
MHDA- 2023/01/17 06:00
CRDT- 2022/09/21 03:02
PHST- 2022/09/22 06:00 [pubmed]
PHST- 2023/01/17 06:00 [medline]
PHST- 2022/09/21 03:02 [entrez]
AID - 10.1176/appi.neuropsych.21080214 [doi]
PST - ppublish
SO  - J Neuropsychiatry Clin Neurosci. 2023 Winter;35(1):98-101. doi: 
      10.1176/appi.neuropsych.21080214. Epub 2022 Sep 21.